Sailing in deceptive calm: Navigating the undercurrents of essential thrombocythaemia

Abstract

The discovery of driver mutations in myeloproliferative neoplasms has significantly contributed to the management of patients with essential thrombocythaemia (ET). High‐quality evidence has started to pave the way for targeted therapy. The review by Ferrer‐Marín et al. further advances this discussion, highlighting how molecular profiling, including non‐driver gene mutations, is set to revolutionize personalized treatment approaches for ET patients.Commentary on: Ferrer‐Marín et al. Essential thrombocythemia: a contemporary approach with new drugs on the horizon. Br J Haematol 2024 (Online ahead of print). doi: 10.1111/bjh.19403.